tiprankstipranks
Trending News
More News >
Roivant Sciences (ROIV)
NASDAQ:ROIV
US Market
Advertisement

Roivant Sciences (ROIV) Stock Forecast & Price Target

Compare
656 Followers
See the Price Targets and Ratings of:

ROIV Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Roivant
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ROIV Stock 12 Month Forecast

Average Price Target

$16.29
▲(26.08% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is $16.29 with a high forecast of $19.00 and a low forecast of $12.00. The average price target represents a 26.08% change from the last price of $12.92.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","11":"$11","14":"$14","17":"$17","20":"$20"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,11,14,17,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.39,12.89846153846154,13.406923076923077,13.915384615384616,14.423846153846155,14.932307692307692,15.44076923076923,15.94923076923077,16.45769230769231,16.966153846153844,17.474615384615383,17.983076923076922,18.49153846153846,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.39,12.690000000000001,12.99,13.290000000000001,13.59,13.89,14.19,14.49,14.79,15.09,15.389999999999999,15.69,15.989999999999998,{"y":16.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.39,12.360000000000001,12.33,12.3,12.27,12.24,12.21,12.18,12.15,12.120000000000001,12.09,12.06,12.03,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$19.00Average Price Target$16.29Lowest Price Target$12.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$16
Buy
23.84%
Upside
Initiated
09/03/25
Positive Outlook for Roivant Sciences Driven by Brepocitinib's Phase 3 Potential and Undervalued StockWe believe the breadth of IST/case studies in the literature are supportive of an efficacy signal for JAK1 inhibition in DM, although we acknowledge the lack of Ph2 proof-of- concept data for brepocitinib adds risk to the readout. The dual targeting of JAK1 and TYK2 could build upon JAK1 inhibition alone. Further, blinded steroid taper data suggests strong clinical execution that could mitigate an outsized placebo response. Ahead of the data, we believe ROIV’s current valuation is pricing in minimal value attributed for brepocitinib, and we see potential for upside on a positive DM readout, which could potentially liberate ROIV shares from the range-bound trading pattern the stock has endured over the last ~1-2 years. Initiate Buy/High Risk, TP $16/shr.
TD Cowen Analyst forecast on ROIV
TD Cowen
TD Cowen
Buy
Reiterated
09/02/25
TD Cowen Sticks to Its Buy Rating for Roivant Sciences (ROIV)
Leerink Partners Analyst forecast on ROIV
Leerink Partners
Leerink Partners
$17$18
Buy
39.32%
Upside
Reiterated
08/12/25
Leerink Partners Keeps Their Buy Rating on Roivant Sciences (ROIV)
H.C. Wainwright Analyst forecast on ROIV
H.C. Wainwright
H.C. Wainwright
$18
Buy
39.32%
Upside
Reiterated
08/12/25
Promising Potential of Roivant Sciences' Brepocitinib and Pipeline Fuels Buy Rating
Guggenheim Analyst forecast on ROIV
Guggenheim
Guggenheim
$15
Buy
16.10%
Upside
Reiterated
08/11/25
Guggenheim Sticks to Its Buy Rating for Roivant Sciences (ROIV)
Bank of America Securities Analyst forecast on ROIV
Bank of America Securities
Bank of America Securities
$12
Hold
-7.12%
Downside
Reiterated
08/11/25
Bank of America Securities Sticks to Their Hold Rating for Roivant Sciences (ROIV)
J.P. Morgan Analyst forecast on ROIV
J.P. Morgan
J.P. Morgan
$16
Buy
23.84%
Upside
Assigned
07/25/25
Roivant Sciences placed on 'Positive Catalyst Watch' at JPMorganRoivant Sciences placed on 'Positive Catalyst Watch' at JPMorgan
Goldman Sachs Analyst forecast on ROIV
Goldman Sachs
Goldman Sachs
$19
Buy
47.06%
Upside
Initiated
07/10/25
Roivant Sciences (ROIV) Initiated with a Buy at Goldman Sachs
Cantor Fitzgerald Analyst forecast on ROIV
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
06/18/25
Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Jefferies Analyst forecast on ROIV
Jefferies
Jefferies
$18
Buy
39.32%
Upside
Reiterated
03/11/25
Strategic Growth Potential in Roivant Sciences: Capitalizing on Graves' Disease Market and FcRn Indications
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$16
Buy
23.84%
Upside
Initiated
09/03/25
Positive Outlook for Roivant Sciences Driven by Brepocitinib's Phase 3 Potential and Undervalued StockWe believe the breadth of IST/case studies in the literature are supportive of an efficacy signal for JAK1 inhibition in DM, although we acknowledge the lack of Ph2 proof-of- concept data for brepocitinib adds risk to the readout. The dual targeting of JAK1 and TYK2 could build upon JAK1 inhibition alone. Further, blinded steroid taper data suggests strong clinical execution that could mitigate an outsized placebo response. Ahead of the data, we believe ROIV’s current valuation is pricing in minimal value attributed for brepocitinib, and we see potential for upside on a positive DM readout, which could potentially liberate ROIV shares from the range-bound trading pattern the stock has endured over the last ~1-2 years. Initiate Buy/High Risk, TP $16/shr.
TD Cowen Analyst forecast on ROIV
TD Cowen
TD Cowen
Buy
Reiterated
09/02/25
TD Cowen Sticks to Its Buy Rating for Roivant Sciences (ROIV)
Leerink Partners Analyst forecast on ROIV
Leerink Partners
Leerink Partners
$17$18
Buy
39.32%
Upside
Reiterated
08/12/25
Leerink Partners Keeps Their Buy Rating on Roivant Sciences (ROIV)
H.C. Wainwright Analyst forecast on ROIV
H.C. Wainwright
H.C. Wainwright
$18
Buy
39.32%
Upside
Reiterated
08/12/25
Promising Potential of Roivant Sciences' Brepocitinib and Pipeline Fuels Buy Rating
Guggenheim Analyst forecast on ROIV
Guggenheim
Guggenheim
$15
Buy
16.10%
Upside
Reiterated
08/11/25
Guggenheim Sticks to Its Buy Rating for Roivant Sciences (ROIV)
Bank of America Securities Analyst forecast on ROIV
Bank of America Securities
Bank of America Securities
$12
Hold
-7.12%
Downside
Reiterated
08/11/25
Bank of America Securities Sticks to Their Hold Rating for Roivant Sciences (ROIV)
J.P. Morgan Analyst forecast on ROIV
J.P. Morgan
J.P. Morgan
$16
Buy
23.84%
Upside
Assigned
07/25/25
Roivant Sciences placed on 'Positive Catalyst Watch' at JPMorganRoivant Sciences placed on 'Positive Catalyst Watch' at JPMorgan
Goldman Sachs Analyst forecast on ROIV
Goldman Sachs
Goldman Sachs
$19
Buy
47.06%
Upside
Initiated
07/10/25
Roivant Sciences (ROIV) Initiated with a Buy at Goldman Sachs
Cantor Fitzgerald Analyst forecast on ROIV
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
06/18/25
Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Jefferies Analyst forecast on ROIV
Jefferies
Jefferies
$18
Buy
39.32%
Upside
Reiterated
03/11/25
Strategic Growth Potential in Roivant Sciences: Capitalizing on Graves' Disease Market and FcRn Indications
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Roivant Sciences

1 Month
xxx
Success Rate
20/33 ratings generated profit
61%
Average Return
+4.74%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.61% of your transactions generating a profit, with an average return of +4.74% per trade.
3 Months
xxx
Success Rate
17/25 ratings generated profit
68%
Average Return
+14.23%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.00% of your transactions generating a profit, with an average return of +14.23% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
30/33 ratings generated profit
91%
Average Return
+37.08%
reiterated a buy rating 26 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +37.08% per trade.
2 Years
xxx
Success Rate
32/33 ratings generated profit
97%
Average Return
+45.79%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 96.97% of your transactions generating a profit, with an average return of +45.79% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ROIV Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
4
4
4
4
3
Buy
7
12
11
10
5
Hold
4
5
7
11
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
21
22
25
18
In the current month, ROIV has received 8 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. ROIV average Analyst price target in the past 3 months is 16.29.
Each month's total comprises the sum of three months' worth of ratings.

ROIV Financial Forecast

ROIV Earnings Forecast

Next quarter’s earnings estimate for ROIV is -$0.32 with a range of -$0.47 to -$0.25. The previous quarter’s EPS was -$0.25. ROIV beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.16% of the time in the same period. In the last calendar year ROIV has Outperformed its overall industry.
Next quarter’s earnings estimate for ROIV is -$0.32 with a range of -$0.47 to -$0.25. The previous quarter’s EPS was -$0.25. ROIV beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.16% of the time in the same period. In the last calendar year ROIV has Outperformed its overall industry.

ROIV Sales Forecast

Next quarter’s sales forecast for ROIV is $5.62M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $2.17M. ROIV beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year ROIV has Outperformed its overall industry.
Next quarter’s sales forecast for ROIV is $5.62M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $2.17M. ROIV beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year ROIV has Outperformed its overall industry.

ROIV Stock Forecast FAQ

What is ROIV’s average 12-month price target, according to analysts?
Based on analyst ratings, Roivant Sciences’s 12-month average price target is 16.29.
    What is ROIV’s upside potential, based on the analysts’ average price target?
    Roivant Sciences has 26.08% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ROIV a Buy, Sell or Hold?
          Roivant Sciences has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Roivant Sciences’s price target?
            The average price target for Roivant Sciences is 16.29. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $19.00 ,the lowest forecast is $12.00. The average price target represents 26.08% Increase from the current price of $12.92.
              What do analysts say about Roivant Sciences?
              Roivant Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of ROIV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis